Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Shares Gap Up – What’s Next?

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) gapped up before the market opened on Tuesday. The stock had previously closed at $13.95, but opened at $14.97. Bayer Aktiengesellschaft shares last traded at $14.95, with a volume of 160,871 shares trading hands.

Analysts Set New Price Targets

Separately, Zacks Research raised Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research note on Friday, July 10th. Two analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Buy”.

Bayer Aktiengesellschaft Price Performance

The firm has a fifty day moving average price of $13.45 and a two-hundred day moving average price of $12.58. The stock has a market capitalization of $60.93 billion, a P/E ratio of -33.71, a PEG ratio of 2.01 and a beta of 0.57. The company has a debt-to-equity ratio of 1.05, a quick ratio of 0.67 and a current ratio of 1.04.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last issued its quarterly earnings results on Tuesday, November 3rd. The company reported $0.11 EPS for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.02). Bayer Aktiengesellschaft had a positive return on equity of 16.34% and a negative net margin of 3.28%. The company had revenue of $11.25 billion during the quarter, compared to analysts’ expectations of $11.21 billion. As a group, analysts expect that Bayer Aktiengesellschaft will post 1.27 EPS for the current fiscal year.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft is a Germany-based life sciences company headquartered in Leverkusen. Founded in 1863 by Friedrich Bayer and Johann Friedrich Weskott, the company develops products in health care and agriculture and serves customers in markets around the world.

Bayer operates through three primary businesses: Pharmaceuticals, Consumer Health and Crop Science. Its Pharmaceuticals segment develops prescription medicines in areas such as cardiovascular disease, women’s health, oncology, hematology and specialty therapies.